Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Suspended 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 595Carcinoma, Renal Cell 276Urinary Bladder Neoplasms 175Kidney Neoplasms 112Neoplasms 101Neoplasm Metastasis 94Carcinoma, Non-Small-Cell Lung 94Carcinoma, Transitional Cell 86Melanoma 85Breast Neoplasms 83Ovarian Neoplasms 64Lung Neoplasms 50Colorectal Neoplasms 50Pancreatic Neoplasms 43Stomach Neoplasms 40Sarcoma 37Squamous Cell Carcinoma of Head and Neck 35Triple Negative Breast Neoplasms 31Testicular Neoplasms 29Uterine Cervical Neoplasms 27Esophageal Neoplasms 26Carcinoma, Hepatocellular 26Head and Neck Neoplasms 24Non-Muscle Invasive Bladder Neoplasms 23Small Cell Lung Carcinoma 22Colonic Neoplasms 20Urologic Neoplasms 17Neuroblastoma 17Multiple Myeloma 17Endometrial Neoplasms 17

Interventions

tasquinimod 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metastatic Castrate Resistant Prostate Cancer × Genitourinary × Clear all
NCT01732549 2019-11-22

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Ipsen

Phase 2 Terminated
144 enrolled 22 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡